Posted inBiotechnology
Racial and Ethnic Disparities in Mortality Causes for Clear Cell Renal Cancer
A new study highlights how race and ethnicity can shape not just cancer risk, but the specific medical reasons behind…
Posted inBiotechnology
In-House 24-Hour Call Shifts Outdated in Modern Workplaces
Hospitals have long relied on the 24-hour “in-house call”—a familiar feature of modern medical staffing in which physicians remain on-site…
Posted inBiotechnology
Study Evaluates Interrater Reliability of the Bayley-4 in Multidisciplinary Teams
A new study is shaking up how clinicians and researchers judge early childhood development tests by showing that results from…
Posted inBiotechnology
Alcohol Intervention Proves Successful in Humanitarian Aid Setting
A new randomized trial offers some of the strongest evidence yet that structured alcohol-reduction care can work in humanitarian settings…
Posted inBiotechnology
Genes Influence Diet Choices and Metabolic Health, New Research Suggests
National Harbor, Md. (July 27, 2026) — Some people seem naturally drawn to sweets and fatty foods, while others can…
Posted inBiotechnology
Grant Funds Brain Imaging Research to Improve Post-Stroke Bladder Treatments
Stroke-related urinary incontinence affects more than a third of survivors and often goes untreated at its neurological source. A new…
Posted inBiotechnology
Study finds how sleep strengthens memory, and epilepsy disrupts the process
Baltimore, July 27, 2026 — A new human study from researchers at the Kennedy Krieger Institute and Johns Hopkins Medicine…
Posted inBiotechnology
Enzyme discovery may help clear deadly zombie cells from human tissues
LA JOLLA (July 24, 2026)—As populations age worldwide, the key challenge is not just living longer but staying healthy longer.…
Posted inBiotechnology
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
Incyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.
Posted inBiotechnology
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
An experimental drug targeting both GLP-1 and glucagon receptors has curbed heavy drinking in a phase 2 trial, providing hope…